Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Enzymatic inhibitors of Janus kinase 2 (JAK2) are in clinical development for the treatment of myeloproliferative neoplasms (MPNs), B cell acute lymphoblastic leukemia (B-ALL) with rearrangements of the cytokine receptor subunit cytokine receptor-like factor 2 (CRLF2), and other tumors with constitutive JAK2 signaling.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP165670.RAq6gwjBndk_g8Efc4SF946wK_46sFGpaUMZA-XX1wDso130_assertion description "[Enzymatic inhibitors of Janus kinase 2 (JAK2) are in clinical development for the treatment of myeloproliferative neoplasms (MPNs), B cell acute lymphoblastic leukemia (B-ALL) with rearrangements of the cytokine receptor subunit cytokine receptor-like factor 2 (CRLF2), and other tumors with constitutive JAK2 signaling.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP165670.RAq6gwjBndk_g8Efc4SF946wK_46sFGpaUMZA-XX1wDso130_provenance.
• NP860253.RATY4_pzOsgXMBNNV7MxaIXs2lLNc7d1GJLmKQbd9SzR0130_assertion description "[Enzymatic inhibitors of Janus kinase 2 (JAK2) are in clinical development for the treatment of myeloproliferative neoplasms (MPNs), B cell acute lymphoblastic leukemia (B-ALL) with rearrangements of the cytokine receptor subunit cytokine receptor-like factor 2 (CRLF2), and other tumors with constitutive JAK2 signaling.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP860253.RATY4_pzOsgXMBNNV7MxaIXs2lLNc7d1GJLmKQbd9SzR0130_provenance.
• NP650205.RAY4gOTlKHzgN0hYQ-m4YOmQ9ogyDQUCBGuM8tm4eDP8I130_assertion description "[Enzymatic inhibitors of Janus kinase 2 (JAK2) are in clinical development for the treatment of myeloproliferative neoplasms (MPNs), B cell acute lymphoblastic leukemia (B-ALL) with rearrangements of the cytokine receptor subunit cytokine receptor-like factor 2 (CRLF2), and other tumors with constitutive JAK2 signaling.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP650205.RAY4gOTlKHzgN0hYQ-m4YOmQ9ogyDQUCBGuM8tm4eDP8I130_provenance.
• NP399608.RAs1UvhJ85cwCAw51rfdNnfaBJjmhh6B5PGBrmv0g8Eb8130_assertion description "[Enzymatic inhibitors of Janus kinase 2 (JAK2) are in clinical development for the treatment of myeloproliferative neoplasms (MPNs), B cell acute lymphoblastic leukemia (B-ALL) with rearrangements of the cytokine receptor subunit cytokine receptor-like factor 2 (CRLF2), and other tumors with constitutive JAK2 signaling.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP399608.RAs1UvhJ85cwCAw51rfdNnfaBJjmhh6B5PGBrmv0g8Eb8130_provenance.
• NP442995.RAuH-bVwpyKlK1_GCDr96vvU2lG9WDKKmIujllvkkkloE130_assertion description "[Enzymatic inhibitors of Janus kinase 2 (JAK2) are in clinical development for the treatment of myeloproliferative neoplasms (MPNs), B cell acute lymphoblastic leukemia (B-ALL) with rearrangements of the cytokine receptor subunit cytokine receptor-like factor 2 (CRLF2), and other tumors with constitutive JAK2 signaling.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP442995.RAuH-bVwpyKlK1_GCDr96vvU2lG9WDKKmIujllvkkkloE130_provenance.
• NP955535.RAA7nFFmj3rny1Gpu25uy1R4Y6ERW8FbZsjAIFpe5Lze4130_assertion description "[Enzymatic inhibitors of Janus kinase 2 (JAK2) are in clinical development for the treatment of myeloproliferative neoplasms (MPNs), B cell acute lymphoblastic leukemia (B-ALL) with rearrangements of the cytokine receptor subunit cytokine receptor-like factor 2 (CRLF2), and other tumors with constitutive JAK2 signaling.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP955535.RAA7nFFmj3rny1Gpu25uy1R4Y6ERW8FbZsjAIFpe5Lze4130_provenance.
• NP884825.RAJfqaa5_b-2QwGhpNCCJ_gUzQEoqIrCoNbCmFtfbbe38130_assertion description "[Enzymatic inhibitors of Janus kinase 2 (JAK2) are in clinical development for the treatment of myeloproliferative neoplasms (MPNs), B cell acute lymphoblastic leukemia (B-ALL) with rearrangements of the cytokine receptor subunit cytokine receptor-like factor 2 (CRLF2), and other tumors with constitutive JAK2 signaling.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP884825.RAJfqaa5_b-2QwGhpNCCJ_gUzQEoqIrCoNbCmFtfbbe38130_provenance.
• NP806305.RA6vFJdoJI4-H2LlYG-qRudOLIZFUqwoaI8PI1fdsKOtM130_assertion description "[Enzymatic inhibitors of Janus kinase 2 (JAK2) are in clinical development for the treatment of myeloproliferative neoplasms (MPNs), B cell acute lymphoblastic leukemia (B-ALL) with rearrangements of the cytokine receptor subunit cytokine receptor-like factor 2 (CRLF2), and other tumors with constitutive JAK2 signaling.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP806305.RA6vFJdoJI4-H2LlYG-qRudOLIZFUqwoaI8PI1fdsKOtM130_provenance.
• NP837492.RA1XyhoBhGp4v2SopAQeJK59_9QKtu07WwN2ztOYRg-cQ130_assertion description "[Enzymatic inhibitors of Janus kinase 2 (JAK2) are in clinical development for the treatment of myeloproliferative neoplasms (MPNs), B cell acute lymphoblastic leukemia (B-ALL) with rearrangements of the cytokine receptor subunit cytokine receptor-like factor 2 (CRLF2), and other tumors with constitutive JAK2 signaling.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP837492.RA1XyhoBhGp4v2SopAQeJK59_9QKtu07WwN2ztOYRg-cQ130_provenance.
• assertion description "[Enzymatic inhibitors of Janus kinase 2 (JAK2) are in clinical development for the treatment of myeloproliferative neoplasms (MPNs), B cell acute lymphoblastic leukemia (B-ALL) with rearrangements of the cytokine receptor subunit cytokine receptor-like factor 2 (CRLF2), and other tumors with constitutive JAK2 signaling.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Enzymatic inhibitors of Janus kinase 2 (JAK2) are in clinical development for the treatment of myeloproliferative neoplasms (MPNs), B cell acute lymphoblastic leukemia (B-ALL) with rearrangements of the cytokine receptor subunit cytokine receptor-like factor 2 (CRLF2), and other tumors with constitutive JAK2 signaling.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Enzymatic inhibitors of Janus kinase 2 (JAK2) are in clinical development for the treatment of myeloproliferative neoplasms (MPNs), B cell acute lymphoblastic leukemia (B-ALL) with rearrangements of the cytokine receptor subunit cytokine receptor-like factor 2 (CRLF2), and other tumors with constitutive JAK2 signaling.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Enzymatic inhibitors of Janus kinase 2 (JAK2) are in clinical development for the treatment of myeloproliferative neoplasms (MPNs), B cell acute lymphoblastic leukemia (B-ALL) with rearrangements of the cytokine receptor subunit cytokine receptor-like factor 2 (CRLF2), and other tumors with constitutive JAK2 signaling.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Enzymatic inhibitors of Janus kinase 2 (JAK2) are in clinical development for the treatment of myeloproliferative neoplasms (MPNs), B cell acute lymphoblastic leukemia (B-ALL) with rearrangements of the cytokine receptor subunit cytokine receptor-like factor 2 (CRLF2), and other tumors with constitutive JAK2 signaling.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Enzymatic inhibitors of Janus kinase 2 (JAK2) are in clinical development for the treatment of myeloproliferative neoplasms (MPNs), B cell acute lymphoblastic leukemia (B-ALL) with rearrangements of the cytokine receptor subunit cytokine receptor-like factor 2 (CRLF2), and other tumors with constitutive JAK2 signaling.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP955536.RAkpZWRTcO162cEGvN6Jm2W_gbcK8tNcuD7madu28RlfA130_assertion description "[Enzymatic inhibitors of Janus kinase 2 (JAK2) are in clinical development for the treatment of myeloproliferative neoplasms (MPNs), B cell acute lymphoblastic leukemia (B-ALL) with rearrangements of the cytokine receptor subunit cytokine receptor-like factor 2 (CRLF2), and other tumors with constitutive JAK2 signaling.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP955536.RAkpZWRTcO162cEGvN6Jm2W_gbcK8tNcuD7madu28RlfA130_provenance.